Lung Cancer Pill Cuts Risk of Dying by Half in Major Trial

A pill for lung cancer has delivered impressive results in newly published research over the weekend. The pill, called osimertinib, was found to cut the risk of dying in half over a five-year span in those who received it alongside surgery. The treatment is intended for patients whose tumors carry a relatively common…

Read more…

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button